Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
when is the water going to boil...when is the paint going to dry..
I follow Napodano on twitter...he just posted an hr or so ago...I like his dd...currently in $CYNA largely based off info he has shared
Napodano has gone independent...away from Zack's... Says not to rely on any previous rating until he confirms...hog
$IDRA looking good lately...hog
$IPCI board...can we delete the spam moderators...hog
Yep...he prolly went back to making french fries...
How's that short position feeling...hog
investorsito Thursday, 07/09/15 01:22:08 PM
Re: None
Post # of 12069
Yes!!! Took my 40% profit and promptly shorted this. Shorty is going to make bank here
Ditto!!!
$IPCI back on track...hog
Amazing
$IPCI up 25%
$IPCI... "FDA rescinds bioequivalence requirement for Intellipharmaceutics' generic Focalin XR
Jul 8 2015, 20:09 ET | By: Douglas W. House, SA News Editor
"Intellipharmaceutics (NASDAQ:IPCI) announces that the FDA has rescinded its requirement that the company must show bioequivalence of its generic Focalin XR (dexmethylphenidate hydrochloride extended-release) capsules in the 5 mg, 10 mg, 20 mg and 40 mg strengths prior to market approval. The firm is unaware of any further action required to receive clearance for its Abbreviated New Drug Application (ANDA) for the product.
This is a welcome reversal for company. On June 18, the agency informed it that bioequivalence would be required."
Huge...thx for posting....hog
Can't say that I am familiar with OCAT other than the price is down like STEM or CUR...just finding that the studies are typically disappointing or maybe just not meeting expectations...maybe too high for the miracle cure that isn't there...and the stocks tank when the cures don't come
Stem cells...they haven't figured them out yet...hog
Damn weez...you should have sold a long time ago....that stock has been disappointing you for some time now...hog
The difference in a "homeless man and his box" and a successful one like doog is in lifting up people, staying positive and having a winning attitude
Bahahaha
I didn't see the SA article...saw the fda wants us to confirm to a new set of guidelines that ipci will need to jump through another hoop but bioavailability is easy....if you have a few extra bucks might be as good buy opportunity...hog
"This is the best box I can afford in a homeless shelter. Waiting on IPCI to change my life if ever." :(".....LtL...hope you bought the crap out of this..you called it...hog
$NVIV my first post on this board looking strong...up a dolla...hog
Does it matter
Jump on em Learn to trade....you called it....I'm with ya....hog
..
This is a monsta!!!!
This morn I gave oxy...keppra...lyrica...and protonix twice...I had 4/pts.I gave 2 coreg last night..hog
Smiling at our pipeline...for those that don't know I'm an RN and I dispense our drugs every night that I work...oxy...lyrica...protonix..keppre effexor...coreg...glucaphage..these are huge....the future is very bright...hog
Added a few...got about all I need ...ready for the fda to start approving some drugs....hog
What if it goes to 2.92???
Agreed...just another hoop to jump through...jump and be done...but if tomorrow the pps drops...I for one will be gobbling up me some shares...see you guys at the hog trough... Hog
Healthcare Day
on June 24, 2015
ROTH Capital Partners to Host Healthcare Day In London on June 24, 2015
Event to Feature One-on-One Meetings Between Institutional Investors and Senior Management Teams Representing Companies Focused on the Biotechnology, Medical Technologies and Specialty Pharmaceuticals Sectors
June 16, 2015 12:15 PM Eastern Daylight Time
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), http://www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Day on Wednesday, June 24, 2015 at the Dorchester Hotel in London, U.K.
“The Life Sciences sector has experienced rapid and significant growth in the past several years with no signs of slowing down. This event is designed to provide investors with direct interactions to management teams of a select group of high quality companies from early to late stage development, through commercialization”
ROTH’s Healthcare Day will give investors the opportunity to interact with senior management of a select group of Life Sciences companies focused in the Biotechnology, Medical Technologies and Specialty Pharmaceuticals sectors.
The event will allow for extensive interaction and on-on-one meetings with management teams, providing in-depth insights into each company.
ROTH biotechnology senior research analysts Joe Pantginis, Ph.D., Elemer Piros, Ph.D., Michael Higgins and Debjit Chattopadhyay, Ph.D., as well as Specialty Pharmaceuticals senior research analyst Scott Henry, CFA and Chris Lewis, Research Analyst – Medical Technologies will be available to discuss their perspectives regarding the companies attending and their views regarding the current healthcare market trends.
“The Life Sciences sector has experienced rapid and significant growth in the past several years with no signs of slowing down. This event is designed to provide investors with direct interactions to management teams of a select group of high quality companies from early to late stage development, through commercialization,” commented John W. Chambers, Vice Chairman and Head of Healthcare Investment Banking at ROTH. “With the expansion of the number of publicly traded companies via an active IPO market, investors have more companies to track. Our goal is to provide investors access to a select number of companies representing a broad range of market capitalizations as well as several newly minted public companies, and to enable investors to further understand their scientific approach, clinical achievements to date and upcoming milestones and catalysts. This event comprising exclusively one-on-one meetings will enable investors to gain direct insight into the key value drivers for this group of innovative companies.”
ROTH has built a leading Healthcare Investment Banking Group over the last several years and has raised approximately $9.7 billion in over 255 Healthcare transactions since 2010. *Past Performance is not indicative of future returns. (Source: ROTH Capital 06/08/2015)
The event is for institutional clients of ROTH and is by invitation only. For more information, please contact your ROTH sales representative at (949) 720-5700 or e-mail: conference@roth.com
Agenda and Events
Wednesday | June 24, 2014
8:00 am - 9:00 am | Morning Coffee
12:00 pm – 1:00 pm | Lunch
9:00 am - 5:00 pm | 1-on-1 / Small Group Meetings
5:00 pm - 7:00 pm | Cocktail Reception
Venue:
The Dorchester
53 Park Lane, Mayfair
London, W1K 1QA, UK
Tel: +44 (0) 20-7629-8888
Participating Companies
The following participating companies are confirmed as of the date of this release:
Bio Blast Pharma Ltd. ORPN
Biodel Inc. BIOD
BioLineRx, Ltd. BLRX
Cempra, Inc. CEMP
Conatus Pharmaceuticals Inc. CNAT
Cortendo AB (publ) OTCNO:CORT
CTI BioPharma Corp. CTIC
Evotec AG EVT
Galmed Pharmaceuticals Ltd. GLMD
IntelliPharmaCeutics International Inc. IPCI
IRadimed Corporation IRMD
Juniper Pharmaceuticals, Inc. JNP
Ligand Pharmaceuticals Incorporated LGND
MacroGenics, Inc. MGNX
Natus Medical Inc. BABY
NeuroDerm Ltd. NDRM
Oxford BioMedica PLC LSE
Pharming Group NV PHARM
RedHill Biopharma Ltd. RDHL
Second Sight Medical Products, Inc. EYES
Spark Therapeutics, Inc. ONCE
Synta Pharmaceuticals Corp. SNTA
TearLab Corporation TEAR
Titan Pharmaceuticals Inc. TTNP
Tonix Pharmaceuticals Holding Corp TNXP
Trinity Biotech plc TRIB
uniQure N.V. QURE
Vectura Group VEC
Event sponsors include Business Wire, Equisolve.Lowenstein Sandler and Vintage.
wouldn't that be a nice surprise...i'm not sure if that's possible or not....but love seeing that stem cells are on topic...hog
Nice news
$CYNA.Tweeting...Jason Napodano, CFA ?@JNapodano 2h2 hours ago
$CYNA prices 5.175M share IPO at $14 per share = ~$72.5M gross (assumes o/a). Expected to close June 23rd. Will trade on NASDAQ tomorrow
Perrin included that they feel they have enough cash to last them until March 31, 2017 at their current spending rate. Their was obviously no mention of a secondary anytime soon and if asked, they wouldn't have been in a position today to comment anyways. My opinion is that they don't do one at all in 2015 as they are still only in the pilot study. And, should they do one next year, let's think about that for a moment. They won't have to dilute the company that much because the stock price will be much higher next year so a few million shares at say, $20 a share, is raising $40 million which would last them about 3 1/2 years (just an example). Recall that the last dilutions were at a much smaller share price so the money raised didn't last that long. In the future, with a higher stock price, we wouldn't have to offer too many shares to be able to raise a large sum of money to fund future endeavors. Not offering too many shares means not that significant a dilution whatsoever on the overall 30 million outstanding shares that exist now.
From NVIV meeting...group on Facebook..Mark discussed the fact that they are in heavy discussion with several Stem cell companies right now. I asked Bill D'Agostino , SR VP of operations, after the meeting in a side bar conversation if he could identify for me whom exactly they are talking with. I didn't expect he would give me any tidbits of info, and he smiled and responded that he could not disclose that information. While on the topic of stem cells, Dr Tom Ulrich stressed the fact that there are several different types of stem cells and that Invivo is pursuing Human GMP neural stem cells, and they are focusing on injectable stem cells. Invivo's number one long term objective is to provide a solution for the $10 billion plus, chronic SCI market with scaffold and stem cell combination. By the way, there current patent doesn't expire until 2027. Invivo is in constant discussions with off shore corporate partnerships. No details available yet. They are also very aware of both EAP & PMA strategies and objectives and view these as pathways to get to commercialization. Too early to discuss timelines since we are still only in the pilot study. As part of their slide presentation they didn't single out AIS scores as the be all, end all gauge of a patients progress but included sensors scores, motor scores, B&B, SCIM III, and MRI measurements. The intent of the pilot and pivotal is both safety and probable benefits. Mark stated that there is a "low bar to approval" meaning they seem extremely confident right now that from what they've already seen, they are very impressed by the resuts. They stated that the FDA is very interested in helping Invivo find a solution for SCI patients as there is no solution that exists right not and that their relationship with the FDA has never been better. The Today show contacted Invivo to ask permission to air the "J & J" segment and Invivo asked the FDA for permission before allowing the Today show to do the story. Invivo sent the "tweezers" to the Today Show w/ FDA blessing.
In regards to the timeframe by which the scaffold should be implanted, Dr Tom Ulrich stated that spinal chord "white matter" is most viable within the first 24 hours. We've seen PT 1 go from AIS A to C after having the implant 8 hours post accident. They set the criteria with the FDA to allow for up to 21 days post accident because they really don't know yet how the timeframe affects a patients progress which is one of the reasons for a study. After the pilot and pivotal, they will have a good idea as to the benefits of a scaffold implant as it relates to the element of time between the accident and the implant. As it would appear to me (my opinion) that it's most beneficial within the first 24 hours, Invivo will find out what type of "diminishing returns" there will be, if any, the longer a patient were to wait for an implant to take place, post accident. Incidentally, there were no further updates on patients 1,2,or 3 provided. Per HIPA regulations, Invivo will not release PT3 name to keep patient privacy intact. On another topic, NVIV will not pursue a duraseal as a means to close the chord after surgery. Most surgeons are either using sutures or a "patch" to close the wound.
All in all, I was very impressed by this management team and they all seem to have their eye, squarely on the prize. A group of us asked one of the directors if a buyout would take place and the response was, " we first need to get the ball over the goal line", and then we'll see what happens. Another investor asked Mark Perrin about institutional investment firms beginning to get more involved, and the possibility of getting Fidelity interested in the company again. Some of you may know Fidelity pulled out when the company was a split adjusted 50 cents. Mark's opinion was that Fidelity would be back on board in the future.Attending the meeting further solidifies my belief that I'm part of company that will achieve success. In talking w/ the management team you could sense their excitement.